Programs & Pipeline ❯ Additional Preclinical Programs

Amicus is committed to continued innovation for all people living with Fabry disease and Pompe disease. As part of our long-term commitment, we have multiple preclinical development programs including an academic research collaboration agreement to explore next generation pharmacological chaperones for Fabry disease, in addition to gene therapies in Pompe and Fabry, respectively.